リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「The effectiveness and retention rate of iguratimod Japanese rheumatoid arthritis patients with/without methotrexate in daily medical care\n」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

The effectiveness and retention rate of iguratimod Japanese rheumatoid arthritis patients with/without methotrexate in daily medical care\n

井上 明日圭 近畿大学

2022.03.02

概要

(1) Background: We evaluated the clinical response of iguratimod (IGU) in patients with rheumatoid arthritis (RA) being treated with or without methotrexate (MTX) over 54 weeks.

(2) Methods: 106 patients with RA undergoing IGU were retrospectively observed. RA patients were divided into those treated with MTX+IGU (n = 35) and those treated with IGU (n = 71). The primary endpoint was the clinical response of the Disease Activity Score assessing 28 joints with C-reactive protein (DAS28-CRP) differences in the changes from baseline to 54 weeks between MTX+IGU and IGU groups. Secondary endpoints, such as the clinical response, retention rate, and safety, were evaluated.

(3) Results: The DAS28-CRP difference in the changes between the two groups were −0.2. DAS28-CRP were significantly reduced from the baseline in the MTX+IGU and IGU groups (−1.43 and −1.20 from baseline, respectively). The retention rates were 71.4% in the MTX+IGU groups and 59.2% in the IGU groups (p = 0.16). Adverse events were observed in a total of 6 (17.1%) MTX+IGU patients and 20 (28.2%) IGU patients (p = 0.21).

(4) Conclusions: IGU therapy may be a useful treatment option for patients who cannot be treated with MTX.

論文の公開元へ

関連論文

関連論文をもっと見る

参考文献

1. Coury, F.F.; Weinblatt, M.E. Clinical trials to establish methotrexate as a therapy for rheumatoid arthritis. Clin. Exp. Rheumatol. 2010, 28, 9–12.

2. Smolen, J.S.; Landewé, R.; Bijlsma, J.W.J.; Burmester, G.R.; Chatzidionysiou, K.; Dougados, M.; Nam, J.L.; Ramiro, S.; Voshaar, M.; Van Vollenhoven, R.F.; et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann. Rheum. Dis. 2017, 76, 960–977. [CrossRef] [PubMed]

3. Van Vollenhoven, R.F.; Geborek, P.; Forslind, K.; Albertsson, K.; Ernestam, S.; Petersson, I.F.; Chatzidionysiou, K.; Bratt, J.; Swefot Study Group. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Lancet 2012, 379, 1712–1720. [CrossRef]

4. Kawakami, A.; Tsuboi, M.; Urayama, S.; Matsuoka, N.; Yamasaki, S.; Hida, A.; Aoyagi, T.; Furuichi, I.; Nakashima, T.; Migita, K.; et al. Inhibitory effect of a new anti-rheumatic drug T-614 on costimulatory molecule expression, cytokine production, and antigen presentation by synovial cells. J. Lab. Clin. Med. 1999, 133, 566–574. [CrossRef]

5. Du, F.; Lü, L.J.; Fu, Q.; Dai, M.; Teng, J.-L.; Fan, W.; Chen, S.-L.; Ye, P.; Shen, N.; Huang, X.-F.; et al. T-614, a novel immunomodulator, attenuates joint inflammation and articular damage in collagen-induced arthritis. Arthritis Res. Ther. 2008, 10, R136. [CrossRef] [PubMed]

6. Kohno, M.; Aikawa, Y.; Tsubouchi, Y.; Hashiramoto, A.; Yamada, R.; Kawahito, Y.; Inoue, K.I.; Kusaka, Y.; Kondo, M.; Sano, H. Inhibitory effect of T-614 on tumor necrosis factor-α induced cytokine production and nuclear factor-κB activation in cultured human synovial cells. J. Rheumatol. 2001, 28, 2591–2596. [PubMed]

7. Luo, Q.; Sun, Y.; Liu, W.; Qian, C.; Jin, B.; Tao, F.; Gu, Y.; Wu, X.; Shen, Y.; Xu, Q. A Novel Disease-Modifying Antirheumatic Drug, Iguratimod, Ameliorates Murine Arthritis by Blocking IL-17 Signaling, Distinct from Methotrexate and Leflunomide. J. Immunol. 2013, 191, 4969–4978. [CrossRef]

8. Tanaka, K.; Yamamoto, T.; Aikawa, Y.; Kizawa, K.; Muramoto, K.; Matsuno, H.; Muraguchi, A. Inhibitory effects of an anti-rheumatic agent T-614 on immunoglobulin production by cultured B cells and rheumatoid synovial tissues engrafted into SCID mice. Rheumatology 2003, 42, 1365–1371. [CrossRef]

9. Aikawa, Y.; Yamamoto, M.; Yamamoto, T.; Morimoto, K.; Tanaka, K. An anti-rheumatic agent T-614 inhibits NF-κB activation in LPS- and TNF-α-stimulated THP-1 cells without interfering with IκBα degradation. Inflamm. Res. 2002, 51, 188–194. [CrossRef]

10. Hara, M.; Abe, T.; Sugawara, S.; Mizushima, Y.; Hoshi, K.; Irimajiri, S.; Hashimoto, H.; Yoshino, S.; Matsui, N.; Nobunaga, M.; et al. Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: A controlled, multicenter, double-blind, parallel-group study. Mod. Rheumatol. 2007, 17, 1–9. [CrossRef]

11. Nozaki, Y.; Inoue, A.; Kinoshita, K.; Funauchi, M.; Matsumura, I. Efficacy of iguratimod vs. salazosulfapyridine as the first-line csDMARD for rheumatoid arthritis. Mod. Rheumatol. 2020, 30, 249–258. [CrossRef]

12. Hara, M.; Ishiguro, N.; Katayama, K.; Kondo, M.; Sumida, T.; Mimori, T.; Soen, S.; Nagai, K.; Yamaguchi, T.; Yamamoto, K.; et al. Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: An open-label extension of a randomized, double-blind, placebo-controlled trial. Mod. Rheumatol. 2014, 24, 410–418. [CrossRef] [PubMed]

13. Ishiguro, N.; Yamamoto, K.; Katayama, K.; Kondo, M.; Sumida, T.; Mimori, T.; Soen, S.; Nagai, K.; Yamaguchi, T.; Hara, M.; et al. Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: A randomized, double-blind, placebo-controlled trial. Mod. Rheumatol. 2013, 23, 430–439. [CrossRef]

14. Hutchinson, D. Classification criteria: The 1987 American Rheumatism Association revised criteria for the classification of rheumatoid arthritis. CPD Rheumatol. 1999, 1, 13–14.

15. Aletaha, D.; Neogi, T.; Silman, A.J.; Funovits, J.; Felson, D.T.; Bingham, C.O., III; Birnbaum, N.S.; Burmester, G.R.; Bykerk, V.P.; Cohen, M.D.; et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010, 62, 2569–2581. [CrossRef] [PubMed]

16. Inoue, E.; Yamanaka, H.; Hara, M.; Tomatsu, T.; Kamatani, N. Comparison of Disease Activity Score (DAS)28- erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values. Ann. Rheum. Dis. 2007, 66, 407–409. [CrossRef] [PubMed]

17. Robins, M.; James, M.A.H. Causal Inference—What if. Found. Agnostic Stat. 2020, 235–281. [CrossRef]

18. Xia, Z.; Lyu, J.; Hou, N.; Song, L.; Li, X.; Liu, H. Iguratimod in combination with methotrexate in active rheumatoid arthritis: Therapeutic effects. Zeitschrift für Rheumatologie 2016, 75, 828–833. [CrossRef] [PubMed]

19. Duan, X.-W.; Zhang, X.-L.; Mao, S.-Y.; Shang, J.-J.; Shi, X.-D. Efficacy and safety evaluation of a combination of iguratimod and methotrexate therapy for active rheumatoid arthritis patients: A randomized controlled trial. Clin. Rheumatol. 2015, 34, 1513–1519. [CrossRef] [PubMed]

20. Okamura, K.; Yonemoto, Y.; Suto, T.; Okura, C.; Takagishi, K. Efficacy at 52 weeks of daily clinical use of iguratimod in patients with rheumatoid arthritis. Mod. Rheumatol. 2015, 25, 534–539. [CrossRef] [PubMed]

21. Ishikawa, K.; Ishikawa, J. Iguratimod, a synthetic disease modifying anti-rheumatic drug inhibiting the activation of NF-κB and production of RANKL: Its efficacy, radiographic changes, safety and predictors over two years’ treatment for Japanese rheumatoid arthritis patients. Mod. Rheumatol. 2019, 29, 418–429. [CrossRef]

22. Suto, T.; Yonemoto, Y.; Okamura, K.; Sakane, H.; Takeuchi, K.; Tamura, Y.; Kaneko, T.; Ayabe, K.; Chikuda, H. The three-year efficacy of iguratimod in clinical daily practice in patients with rheumatoid arthritis. Mod. Rheumatol. 2019, 29, 775–781. [CrossRef]

23. Mimori, T.; Harigai, M.; Atsumi, T.; Fujii, T.; Kuwana, M.; Matsuno, H.; Momohara, S.; Takei, S.; Tamura, N.; Takasaki, Y.; et al. Safety and effectiveness of iguratimod in patients with rheumatoid arthritis: Final report of a 52-week, multicenter postmarketing surveillance study. Mod. Rheumatol. 2019, 29, 314–323. [CrossRef] [PubMed]

24. Mimori, T.; Harigai, M.; Atsumi, T.; Fujii, T.; Kuwana, M.; Matsuno, H.; Momohara, S.; Takei, S.; Tamura, N.; Takasaki, Y.; et al. Safety and effectiveness of 24-week treatment with iguratimod, a new oral disease-modifying antirheumatic drug, for patients with rheumatoid arthritis: Interim analysis of a post-marketing surveillance study of 2679 patients in Japan. Mod. Rheumatol. 2017, 27, 755–765. [CrossRef] [PubMed]

25. Hara, M.; Abe, T.; Sugawara, S.; Mizushima, Y.; Hoshi, K.; Irimajiri, S.; Hashimoto, H.; Yoshino, S.; Matsui, N.; Nobunaga, M. Long-term safety study of iguratimod in patients with rheumatoid arthritis. Mod. Rheumatol. 2007, 17, 10–16. [CrossRef] [PubMed]

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文
を
一発検索！

この論文の関連論文を見る